. Author manuscript; available in PMC: 2021 Aug 14.

Published in final edited form as: ACS Infect Dis. 2020 Jul 14;6(8):2169–2180. doi: 10.1021/acsinfecdis.0c00258

Table 5.

Antimicrobial activity of equimolar mixtures of CBP-vancomycin (2) and C-terminus vancomycin analogues (3, 5 and 9) against VanA E. faecium, presented alongside the individual activity of compounds 2, 3, 4, 5, 9, 15, 19, MIC (μg/mL).

Compound	VanA E. faecium
Compound	ATCC BAA-2317
CBP-vancomycin (2)	2.5
G3-vancomycin (5)	4
G3-CBP-vancomycin (15)	0.3
CBP-vancomycin (2) + G3-vancomycin (5)	2.5 + 2.5
GBn-vancomycin (9)	4
GBn-CBP-vancomycin (19)	0.3
CBP-vancomycin (2) + GBn-vancomycin (9)	2.5 + 2.5
C1-vancomycin (3)	31
C1-CBP-vancomycin (4)	0.3
CBP-vancomycin (2) + C1-vancomycin (3)	2.5 + 2.5